Clinical trials: in Morocco
Hypertension
Efficacy of Irbesartan/Hydrochlorothiazide Versus Valsartan/Hydrochlorothiazide in Mild to Moderate Hypertension
The primary objective is to compare the efficacy of irbesartan/hydrochlorothiazide 300/25mg against valsartan/hydrochlorothiazide 160/25mg in reducing mean systolic blood pressure (SBP) as measured by home blood pressure…
- Trial name
- COSIMA2 (NCT00500604)
- Testing
- Irbesartan/hydrochlorothiazide, Valsartan/hydrochlorothiazide, Hydrochlorothiazide
- Where
- 14 sites in Egypt, Hong Kong and 12 more
- Volunteers
- 1,617 people
- Sponsor
- Sanofi
Hypertension
ACTUAL: Efficacy and Safety of Irbesartan/Hydrochlorothiazide Combination
To compare the antihypertensive efficacy of the combination irbesartan/hydrochlorothiazide (HCTZ) using either a usual or an active elective titration regimen.
- Trial name
- ACTUAL (NCT00708344)
- Testing
- Irbesartan - Hydrochlorothiazide
- Where
- 16 sites in Algeria, Argentina and 14 more
- Volunteers
- 832 people
- Sponsor
- Sanofi
Atrial Fibrillation
Efficacy & Safety of Dronedarone Versus Amiodarone for the Maintenance of Sinus Rhythm in Patients With Atrial Fibrillation
The objective of this study is to compare the efficacy and safety of dronedarone to that of amiodarone for the treatment of patients with atrial fibrillation.
- Trial name
- DIONYSOS (NCT00489736)
- Testing
- dronedarone (SR33589), amiodarone
- Where
- 23 sites in United States, Argentina and 21 more
- Volunteers
- 504 people
- Sponsor
- Sanofi
Atrial Fibrillation, Atrial Flutter
A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation
To assess the efficacy of dronedarone in preventing cardiovascular hospitalization or death from any cause in a population of high-risk patients with atrial fibrillation/atrial flutter (AF/AFL).
- Trial name
- ATHENA (NCT00174785)
- Testing
- dronedarone (SR33589)
- Where
- 37 sites in United States, Argentina and 35 more
- Volunteers
- 4,628 people
- Sponsor
- Sanofi
Head and Neck Neoplasms
NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)
Primary Objective: To estimate the overall response rate after neo-adjuvant chemotherapy of Docetaxel 75 mg/m2 in combination with Cisplatin 75 mg/m2 given for 3 cycles, and followed by conventional radiotherapy in UCNT.
- Trial name
- NCT00916097
- Testing
- DOCETAXEL(XRP6976)
- Where
- 3 sites in Algeria, Morocco and 1 more
- Volunteers
- 66 people
- Sponsor
- Sanofi
Major Depressive Disorders
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder
Primary objective: To evaluate the long-term safety and tolerability of SR58611A (amibegron) patients with major depressive disorder (MDD).
- Trial name
- NCT00855530
- Testing
- amibegron (SR58611A)
- Where
- 11 sites in Argentina, Chile and 9 more
- Volunteers
- 527 people
- Sponsor
- Sanofi
Major Depressive Disorder
Efficacy and Safety of SR58611A co-Administered With Escitalopram in Adults With Major Depressive Disorder
The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs. placebo in patients with Major Depressive Disorder who are on concomitant treatment with escitalopram.
- Trial name
- ALBERIO (NCT00432614)
- Testing
- SR58611A, escitalopram
- Where
- 13 sites in Belgium, Estonia and 11 more
- Volunteers
- 510 people
- Sponsor
- Sanofi
Parkinson Disease
Study of the Effect of SR57667B on the Progression of Symptoms in Patients With Parkinson's Disease
The primary objective is to assess the effect of SR57667B at the dose of 4 mg/d on the progression of Parkinson symptoms in patients with early PD.
- Trial name
- NCT00228150
- Testing
- SR57667B
- Where
- 13 sites in Austria, Canada and 11 more
- Volunteers
- 564 people
- Sponsor
- Sanofi